Prolor Biotech

News

OPKO Health To Acquire PROLOR Biotech
4/24/2013 2:00:00 AM
PROLOR Biotech Receives Notice of Allowance For New U.S. Patent Covering Long-Acting Coagulation Factors VII and IX
4/8/2013 7:30:00 AM
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Methods for Decreasing Body Fat with hGH-CTP
3/5/2013 7:30:00 AM
Free Research Reports on ALB, PBTH, RATE and WFR Issued by the Bedford Report
2/14/2013 8:15:00 AM
PROLOR Biotech's Longer-acting Human Growth Hormone Receives Orphan Drug Designation in Europe
2/13/2013 7:30:00 AM
PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
2/6/2013 7:30:00 AM
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Broad Applications of its CTP Platform for Long Acting Therapeutic Proteins
1/7/2013 7:30:00 AM
PROLOR Biotech To Present At Oppenheimer 23rd Annual Healthcare Conference
12/10/2012 7:30:00 AM
PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
12/7/2012 7:30:00 AM
New Patent Covering PROLOR's Reversible-Pegylation Platform Technology is Allowed by U.S. Patent Office
11/13/2012 7:30:00 AM
PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At Congress Of The GRS And IGF Society
10/18/2012 7:30:00 AM
PROLOR Biotech Announces Positive Results From Preclinical Toxicology Study Of Its Reversible-Pegylation Platform Technology
10/16/2012 7:30:00 AM
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent for Its Long-Acting Human Growth Hormone
10/3/2012 7:30:00 AM
PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
9/21/2012 7:30:00 AM
PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
9/13/2012 7:40:00 AM
PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
7/10/2012 7:30:00 AM
PROLOR Biotech To Present Data On Its Long-Acting Clotting Factors At Leading International Scientific Conference
6/29/2012 7:30:00 AM
Data From Phase II Trial of Prolor Biotech's Long-acting Human Growth Hormone Presented at Endo 2012
6/26/2012 7:30:00 AM
PROLOR Biotech to Present at Jefferies 2012 Global Health Care Conference
5/30/2012 7:30:00 AM
PROLOR Biotech Announces Closing Of Underwritten Public Offering And Exercise Of Underwriters' Overallotment Option
5/16/2012 9:56:00 AM
PROLOR Biotech Announces Pricing of Public Offering of Common Stock
5/11/2012 8:46:00 AM
PROLOR Biotech Announces Proposed Public Offering Of Common Stock
5/10/2012 4:17:00 PM
PROLOR Biotech Announces Top-Line Results from Four-Month Treatment Extension of its Long-Acting Human Growth Hormone Phase II Trial
5/7/2012 8:00:00 AM
PROLOR Biotech Receives Letter from NYSE Amex Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
4/20/2012 4:30:00 PM
PROLOR Biotech Announces Positive Results of Its Obesity/Diabetes Drug Candidate in Preclinical Weight Loss Study
4/17/2012 7:30:00 AM
PROLOR Biotech Initiates Phase II Trial of its Long-Acting Human Growth Hormone in Children with Growth Hormone Deficiency
3/20/2012 7:30:00 AM
PROLOR Biotech to Present Preclinical Data on Its Long-Acting Clotting Factors VIIa and IX at European Hemophilia Conference
2/23/2012 7:30:00 AM
PROLOR Biotech to Present at 2012 Citi Global Health Care Conference
2/22/2012 7:30:00 AM
PROLOR Biotech Announces Positive Preclinical Results from Comparative Study of its Long-Acting Clotting Factor VIIa
2/14/2012 7:30:00 AM
PROLOR Biotech Announces Positive Top-Line Results From Pilot Study of Its Long-Acting Human Growth Hormone Injected Twice Per Month
1/18/2012 7:30:00 AM
PROLOR Biotech to Present at Oppenheimer 22nd Annual Healthcare Conference
12/7/2011 7:30:00 AM
PROLOR Biotech to Present at Lazard Capital Markets 8th Annual Healthcare Conference
11/8/2011 7:30:00 AM
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering its Longer-Acting CTP-Modified Interferons
10/11/2011 7:30:00 AM
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Production and Manufacturing Processes for its Long-acting Human Growth Hormone
10/3/2011 7:30:00 AM
PROLOR Biotech to Present at Jefferies 2011 Global Healthcare Conference
9/21/2011 7:30:00 AM

Stock Information

Symbol: PBTH

Prolor Biotech, Inc.
Last Price 6.43
Change -0.01
Bid N/A
Ask N/A
High 6.50
Low 4:00pm - 6.43
Volume 165038
Last Update 5/22/2013 10:27:36 PM

Media

A Video Overview of PROLOR Biotech
Video Interview with Shai Novik, President of PROLOR Biotech